H.C. Wainwright lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $13 from $20 and keeps a Buy rating on the shares after the company announced the discontinuation of its independent development of FHD-286 in combination with decitabine for patients with relapsed and/or refractory acute myeloid leukemia. The firm is still believers in the BAF targeting thesis and sees Foghorns FHD-909 “as being able to still de-risk the strategy.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FHTX:
- Foghorn Therapeutics price target lowered to $14 from $18 at Jefferies
- Foghorn Therapeutics Advances Precision Oncology Pipeline
- Foghorn to discontinue independent development of FHD-286 with decitabine in AML
- Foghorn Therapeutics (FHTX) Collaborates with Eli Lilly and Surpasses Q3 Expectations
- Foghorn Therapeutics Reports Third Quarter Highlights